Standout Papers
Citation Impact
Citing Papers
High burden and pervasive positive selection of somatic mutations in normal human skin
2015 StandoutScience
Hyperplasia and Carcinomas in Pten-Deficient Mice and Reduced PTEN Protein in Human Bladder Cancer Patients
2006 StandoutNobel
Characteristics and Clinical Impacts of the Immune Environments in Colorectal and Renal Cell Carcinoma Lung Metastases: Influence of Tumor Origin
2013
Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
2009 Standout
Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC) - gastrointestinal cancer group
2008
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Ageing populations: the challenges ahead
2009 Standout
Retinoblastoma-binding protein 2 (RBP2) is frequently expressed in neuroendocrine tumors and promotes the neoplastic phenotype
2016
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
2010 Standout
Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer
2005
Gastric cancer
2016 Standout
Recent trends of cancer in Europe: A combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s
2008
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
2007 Standout
Smarter drugs emerging in pancreatic cancer therapy
2014
Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
2011
Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification
2012
Treatment Decisions After Diagnosis of Metastatic Colorectal Cancer
2011
Cisplatin or Not in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis
2013
Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer
2006 Standout
A view on drug resistance in cancer
2019 StandoutNature
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
2011 Standout
Microsatellite Instability in Colorectal Cancer
2010 Standout
Recent trends in colorectal cancer mortality in Europe
2010
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial
2017
Pancreatic cancer
2020 Standout
A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial
2005
Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours
2009
The biology and management of non-small cell lung cancer
2018 StandoutNature
Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial
2009
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 Standout
Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer
2015 StandoutNature
Precision Diagnosis and Treatment for Advanced Non–Small-Cell Lung Cancer
2017
Pancreatic cancer
2016 Standout
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
2011 Standout
Chemotherapy for advanced gastric cancer
2010
Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study
2018
Colorectal cancer
2013 Standout
The oligometastatic state—separating truth from wishful thinking
2014
Pancreatic Adenocarcinoma
2014 Standout
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016
Global cancer statistics
2011 Standout
Elimination of large tumors in mice by mRNA-encoded bispecific antibodies
2017 StandoutNobel
Randomized phase II study of irinotecan, leucovorin and 5-fluorouracil (ILF) versus cisplatin plus ILF (PILF) combination chemotherapy for advanced gastric cancer
2007
Endpoints in cancer clinical trials
2014
Well-Differentiated Pancreatic Nonfunctioning Tumors/Carcinoma
2006
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
2010 Standout
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
2010 Standout
Emerging Biological Principles of Metastasis
2017 Standout
IFNβ-dependent increases in STAT1, STAT2, and IRF9 mediate resistance to viruses and DNA damage
2013 StandoutNobel
Cancer mortality in Europe, 2005–2009, and an overview of trends since 1980
2013
A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction
2009
Update on the treatment of neuroendocrine tumors
2003
Interventional treatment of neuroendocrine liver metastases
2008
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial
2012 Standout
Gastric cancer
2020 Standout
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
2017
Impact of chemotherapy on quality of life in patients with metastatic esophagogastric cancer
2010
Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients With Chemotherapy-Induced Painful Peripheral Neuropathy
2013 Standout
Pancreatic Cancer
2010 Standout
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Altered expression of cell proliferation-related and interferon-stimulated genes in colon cancer cells resistant to SN38
2008
Somatostatin Analog Therapy in Treatment of Gastrointestinal Disorders and Tumors
2003
Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival
2008
Lessons learned from independent central review
2008
Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
2017 Standout
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
2011 Standout
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
2008 Standout
Health-related quality of life in elderly patients with advanced non-small cell lung cancer comparing carboplatin and weekly paclitaxel doublet chemotherapy with monotherapy
2016
A Subpopulation of CD26+ Cancer Stem Cells with Metastatic Capacity in Human Colorectal Cancer
2010
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction
2008
Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study
2008
Treatment of Liver Tumors with Lipiodol TACE: Technical Recommendations from Experts Opinion
2015
Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans
2005
Tumour heterogeneity and resistance to cancer therapies
2017 Standout
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
2018 Standout
Autochthonous tumors driven by Rb1 loss have an ongoing requirement for the RBP2 histone demethylase
2018 StandoutNobel
SERS/NIR‐II Optical Nanoprobes for Multidimensional Tumor Imaging from Living Subjects, Pathology, and Single Cells and Guided NIR‐II Photothermal Therapy
2022
Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease
2010 Standout
Chemotherapy in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis Based on Aggregate Data
2006
Supramolecular Hydrogelators and Hydrogels: From Soft Matter to Molecular Biomaterials
2015 Standout
NCCN Task Force Report: Evaluating the Clinical Utility of Tumor Markers in Oncology
2011
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
2011 Standout
Weekly Infusional High-Dose Fluorouracil (HD-FU), HD-FU Plus Folinic Acid (HD-FU/FA), or HD-FU/FA Plus Biweekly Cisplatin in Advanced Gastric Cancer: Randomized Phase II Trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie
2007
A Perspective on Cancer Cell Metastasis
2011 StandoutScience
Cancer statistics in China, 2015
2016 Standout
Chemotherapy for advanced gastric cancer
2017 Standout
Claudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody Development
2008
Safety of cisplatin combined with continuous 5-FU versus bolus 5-FU and leucovorin, in metastatic gastrointestinal cancer (FFCD 9404 randomised trial).
2006
Meta-Analyses of Chemotherapy for Locally Advanced and Metastatic Pancreatic Cancer
2007
NCCN Task Force Report: Management of Neuropathy in Cancer
2009
Role of chemotherapy for advanced/recurrent gastric cancer: An individual-patient-data meta-analysis
2013
Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial
2005
Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma
2009
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Prospective, Randomized, Multicenter, Phase III Study of Fluorouracil, Leucovorin, and Irinotecan Versus Epirubicin, Cisplatin, and Capecitabine in Advanced Gastric Adenocarcinoma: A French Intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) Study
2014
Cancer incidence, survival and mortality: Explaining the concepts
2014
Global cancer statistics, 2012
2015 Standout
Photothermal Nanomaterials: A Powerful Light-to-Heat Converter
2023 Standout
Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy
2003
Works of Emmanuel Mitry being referenced
Arterial phase enhancement and body mass index are predictors of response to chemoembolisation for liver metastases of endocrine tumours
2006
Epidemiology, management and prognosis of colorectal cancer with lung metastases: a 30-year population-based study
2010
Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases
2007
Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma
2010
Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients
2004
Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours
2001
Chemotherapy as initial treatment of locally advanced unresectable pancreatic cancer: a valid option?
2007
Role of microsatellite instability in the management of colorectal cancers
2012
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
2017 Standout
Identification in Daily Practice of Patients With Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer): Revised Bethesda Guidelines-Based ApproachVersusMolecular Screening
2008
Epidemiology, treatment and chemoprevention in colorectal cancer
2003
Combination of folinic acid, 5-fluorouracil bolus and infusion, and cisplatin (LV5FU2-P regimen) in patients with advanced gastricor gastroesophageal junction carcinoma
2004
Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma
2002
Pulmonary Resection for Metastases of Colorectal Adenocarcinoma
2010
No evidence of somatic FGFR3 mutation in various types of carcinoma
2001
Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin
1999
Survival from bladder cancer in England and Wales up to 2001
2008
Complete Response of Colorectal Liver Metastases After Chemotherapy: Does It Mean Cure?
2006
Randomized Multicenter Phase II Trial of a Biweekly Regimen of Fluorouracil and Leucovorin (LV5FU2), LV5FU2 Plus Cisplatin, or LV5FU2 Plus Irinotecan in Patients With Previously Untreated Metastatic Gastric Cancer: A Fédération Francophone de Cancérologie Digestive Group Study—FFCD 9803
2004
Oral tyrosine kinase inhibitor masitinib in combination with gemcitabine in patients with advanced pancreatic cancer: A multicenter phase II study
2009
Colorectal cancer chemotherapy: irinotecan.
2000
Adjuvant Chemotherapy After Potentially Curative Resection of Metastases From Colorectal Cancer: A Pooled Analysis of Two Randomized Trials
2008
Efficacy of venlafaxine for the prevention and relief of acute neurotoxicity of oxaliplatin: Results of EFFOX, a randomized, double-blinded, placebo-controlled prospective study
2009